New EU Filings
Executive Summary
Tabelecleucel, Atara Biotherapeutics’ advanced therapy for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
You may also be interested in...
Seventeen And Counting – Bumper Crop Of New EU Filings
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
Advanced Therapy Developers Urged To Monitor Major EU Proposal On Using Blood, Tissues & Cells
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.
Accelerated Assessment Dry Spell Over As EMA Says Yes To Pharming’s Leniolisib
Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.